Achal Patel, Mercer University College of Pharmacy
It is reported that migraines are the third most prevalent illness in the world, prominently affecting women.  Symptoms include visual disturbances, extreme sensitivity to sound, light, touch, and smell, and tingling or numbness in the extremities and face.  Migraines can be classified as either episodic (< 15 headache days/month) or chronic (≤ 15 headache days/month). 
Erenumab is a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor that is involved in migraine pathophysiology through nociceptive mechanisms in the trigeminovascular system.  In a prior phase two trial, erenumab has shown a reduction in the number of episodic migraines at monthly doses of 70 mg and 140 mg. 
Shawn Yee, Mercer University College of Pharmacy
Migraine is a common neurological disorder that is ranked top 10 in terms of global disease burden.  The term migraine can be categorized into either episodic (< 15 migraine or headache days per month) or chronic (≥ 15 headache days per month, with ≥ eight days of migraine days).  Patients with debilitating or frequent migraines are eligible for preventative treatment; however, none of these options target the pathophysiologic pathways involved in migraines. 
Erenumab is a fully human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, which is involved in migraine pathophysiology of the trigeminovascular system.  There are other monoclonal antibodies targeting CGRP, such as fremanezumb that have shown safety and efficacy in migraine prevention. Erenumab in particular, has also demonstrated efficacy in reducing the number of migraine days per month at doses ranging from 70 mg to 140 mg per month in a prior phase II trial. [3,4] Below is the summary of a phase III trial.